View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
January 20, 2022

NuvoAir secures additional $11m Series A raise for clinical trials platform

NuvoAir will unitise the funds to accelerate the clinical services launch with risk-bearing providers and Health Plans.

Digital healthcare company NuvoAir has raised $11m funding as an extension of the Series A round, announced in June last year, to expand the patient-centric care and clinical trials platform.

This brings the total funding raised by the company in Series A round to $25m.

The funding was led by Hikma Ventures, a venture capital arm of Hikma Pharmaceuticals, with participation from new strategic investors and existing investors.

NuvoAir will utilise the funds to expand its team and clinical trials platform, and speed up its clinical services launch with risk-bearing providers and Health Plans.

The company also plans to launch new clinical trial partnerships worldwide.

NuvoAir founder and CEO Lorenzo Consoli said: “We are really excited to have Hikma Ventures join our existing investors to help us expand our unique service model and technology to support a truly patient focused approach to delivering clinical care and clinical trials.”

The company is focused on treating complex patients, with an initial focus on respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD).

As a part of the chronic care ecosystem, NuvoAir launched Aos sensor as an add-on sensor for asthma and COPD inhalers in December last year.

The Aos sensor provides additional data that allows NuvoAir Care Coordinators and healthcare providers to evaluate inhaler technique, monitor inhaler use and assess effectiveness of the treatment.

NuvoAir Board chairman Gary Kurtzman said: “Healthcare is far too confusing and fragmented to navigate, particularly for complex patients who often suffer multiple comorbidities.

“The solution lies in redesigning the experience around the patient, thereby providing a more empathetic and coordinated approach to their care.”

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU